 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...888990919293949596979899100» |
- letrozole / Generic mfg.
New P2/3 trial: Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment (clinicaltrials.gov) - Feb 20, 2013
P2/3, N=50, Recruiting, Sponsor: Helsinki University Central Hospital
- | metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Feb 20, 2013
P2, N=64, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | everolimus / Generic mfg.
Trial initiation date: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Feb 18, 2013
P3, N=3500, Recruiting, Sponsor: Southwest Oncology Group
Initiation date: Sep 2012 --> Apr 2013
- | fexagratinib (ABSK091) / Abbisko
New P1/2 trial, Combination therapy: AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL) (clinicaltrials.gov) - Feb 13, 2013
P1/2, N=99, Recruiting, Sponsor: Imperial College London
- Piqray (alpelisib) / Novartis
New P1 trial: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 13, 2013
P1, N=30, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
- letrozole / Generic mfg.
Biomarker, Trial initiation date: Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer (clinicaltrials.gov) - Feb 7, 2013
P2, N=115, Active, not recruiting, Sponsor: Washington University School of Medicine
Initiation date: Sep 2012 --> Apr 2013 Initiation date: Sep 2002 --> Oct 2003
- letrozole / Generic mfg.
Biomarker, Enrollment change: Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer (clinicaltrials.gov) - Feb 7, 2013
P2, N=115, Active, not recruiting, Sponsor: Washington University School of Medicine
Initiation date: Sep 2002 --> Oct 2003 N=150 --> 115
- ||||| New P2 trial, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Feb 3, 2013
P2, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
- | letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., zoledronic acid / Generic mfg.
Enrollment change: Extended Endocrine Therapy for Premenopausal Women With Breast Cancer (clinicaltrials.gov) - Jan 29, 2013
P2, N=17, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
N=150 --> 115 N=50 --> 17
- estradiol valerate / Generic mfg.
Clinical: The Effects of Two Endometrium Preparation Protocols in Frozen-thawed Embryo Transfer in Women With Irregular Cycles (clinicaltrials.gov) - Jan 29, 2013
P=N/A, N=670, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., zoledronic acid / Generic mfg.
Enrollment closed: Extended Endocrine Therapy for Premenopausal Women With Breast Cancer (clinicaltrials.gov) - Jan 29, 2013
P2, N=17, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
N=50 --> 17 Recruiting --> Active, not recruiting
- letrozole / Generic mfg.
Enrollment open: Aromatase Inhibitor Host Factors Study (clinicaltrials.gov) - Jan 22, 2013
P=N/A, N=140, Recruiting, Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche, Zelboraf (vemurafenib) / Roche
New P2 trial: SHIVA: A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer (clinicaltrials.gov) - Jan 16, 2013
P2, N=1000, Recruiting, Sponsor: Institut Curie
- KW-2450 / Kyowa Kirin
Trial termination, Combination therapy, Metastases: Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 9, 2013
P1/2, N=11, Terminated, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; The results of the dose escalation phase did not identify a well-tolerated dose that would permit further study in Phase 2.
- KW-2450 / Kyowa Kirin
Enrollment change, Combination therapy, Metastases: Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 9, 2013
P1/2, N=11, Terminated, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Active, not recruiting --> Terminated; The results of the dose escalation phase did not identify a well-tolerated dose that would permit further study in Phase 2. N=198 --> 11
- || Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, pictilisib (GDC-0941) / Roche
Enrollment change: A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 9, 2013
P1, N=64, Active, not recruiting, Sponsor: Genentech
N=198 --> 11 N=24 --> 64
- | Enrollment closed: MINDACT: Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes (clinicaltrials.gov) - Jan 9, 2013
P3, N=6600, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=24 --> 64 Recruiting --> Active, not recruiting
- || letrozole / Generic mfg., tamoxifen / Generic mfg.
New P3 trial: Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors (clinicaltrials.gov) - Dec 30, 2012
P3, N=360, Recruiting, Sponsor: Postgraduate Institute of Medical Education and Research
- metformin / Generic mfg., letrozole / Generic mfg.
Enrollment open: Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer (clinicaltrials.gov) - Dec 17, 2012
P2, N=208, Recruiting, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD)
Enrollment open, Metastases: Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy (clinicaltrials.gov) - Dec 5, 2012
P=N/A, N=14, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Ibrance (palbociclib) / Pfizer
New P3 trial, IO biomarker, Metastases: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) (clinicaltrials.gov) - Dec 2, 2012
P3, N=450, Recruiting, Sponsor: Pfizer
- | Soltamox (tamoxifen citrate) / Jazz
Enrollment closed: Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (clinicaltrials.gov) - Dec 2, 2012
P3, N=11248, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- PF-04691502 / Pfizer
Trial termination, Combination therapy, IO biomarker: Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer (clinicaltrials.gov) - Nov 28, 2012
P2, N=14, Terminated, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Terminated; See termination reason in detailed description.
- | Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment closed: CALGB-40503: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (clinicaltrials.gov) - Nov 27, 2012
P3, N=502, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated; See termination reason in detailed description. Completed --> Active, not recruiting
- ||| BMS-754807 / BMS
Enrollment closed: Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors (clinicaltrials.gov) - Nov 7, 2012
P2, N=100, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- Biomarker, Enrollment open: MIRHO: Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer (clinicaltrials.gov) - Nov 5, 2012
P4, N=39, Recruiting, Sponsor: Institut Claudius Regaud
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | rhGH-Emisphere (somatropin oral, oral recombinant human growth hormone) / Novo Nordisk, Ligand, Genotropin (somatropin) / Pfizer, Nutropin AQ (somatropin) / Ipsen, Roche
Enrollment closed, Combination therapy: ThrasherAI: Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature (clinicaltrials.gov) - Oct 30, 2012
P3, N=77, Active, not recruiting, Sponsor: Nemours Children's Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Ibrance (palbociclib) / Pfizer
New P2 trial, Combination therapy: Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women (clinicaltrials.gov) - Oct 16, 2012
P2, N=45, Recruiting, Sponsor: Organisation for Oncology and Translational Research
- ||||| letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Oct 1, 2012
P2, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
- luminespib (AUY922) / Ligand
Trial withdrawal: AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=0, Withdrawn, Sponsor: Texas Tech University Health Sciences Center
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- luminespib (AUY922) / Ligand
Enrollment change: AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=0, Withdrawn, Sponsor: Texas Tech University Health Sciences Center
Recruiting --> Withdrawn N=49 --> 0
- letrozole / Generic mfg., tamoxifen / Generic mfg.
Enrollment change: Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Sep 24, 2012
P=N/A, N=56, Completed, Sponsor: University of California, San Francisco
N=49 --> 0 N=40 --> 56
- metformin / Generic mfg., letrozole / Generic mfg.
New P1 trial: Study to Compare Between Combimed Metformin-letrozole and Ovarian Drilling in Pcos With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Sep 24, 2012
P1, N=146, Completed, Sponsor: Zagazig University
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Metastases: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=177, Active, not recruiting, Sponsor: Pfizer
N=40 --> 56 Recruiting --> Active, not recruiting
- | letrozole / Generic mfg.
New P1/2 trial: T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin (clinicaltrials.gov) - Sep 16, 2012
P1/2, N=60, Recruiting, Sponsor: University of Washington
- ||||| Ibrance (palbociclib) / Pfizer
New P1/2 trial, Combination therapy, Metastases: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Sep 10, 2012
P1/2, N=58, Active, not recruiting, Sponsor: Pfizer
- metformin / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
Clinical: Letrozole or Combined Clomiphene Citrate Metformin as a First Line Treatment in Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=200, Completed, Sponsor: Assiut University
- || everolimus / Generic mfg.
New P3 trial: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Aug 26, 2012
P3, N=3500, Recruiting, Sponsor: Southwest Oncology Group
- linsitinib (ASP7487) / Sling Therap
Trial termination, Combination therapy, Metastases: Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer (clinicaltrials.gov) - Aug 9, 2012
P2, N=11, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; PI closed study early, all patients experienced severe toxicities and progressed
- ||| samotolisib (LY3023414) / Eli Lilly
Enrollment open, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Aug 8, 2012
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Terminated; PI closed study early, all patients experienced severe toxicities and progressed Not yet recruiting --> Recruiting
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Enrollment closed: AMIGOS: Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation (clinicaltrials.gov) - Aug 8, 2012
P3, N=900, Active, not recruiting, Sponsor: Yale University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- letrozole / Generic mfg., erlotinib / Generic mfg.
Trial termination, Metastases: Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer. (clinicaltrials.gov) - Aug 2, 2012
P2, N=48, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; low accrual
- ||| samotolisib (LY3023414) / Eli Lilly
New P1 trial, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Jul 30, 2012
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
- | letrozole / Generic mfg., exemestane / Generic mfg.
New P2 trial, Metastases: Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer (clinicaltrials.gov) - Jul 29, 2012
P2, N=60, Recruiting, Sponsor: Xichun Hu
- letrozole / Generic mfg.
Enrollment closed: SOLE-EST: Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07 (clinicaltrials.gov) - Jul 19, 2012
P=N/A, N=100, Active, not recruiting, Sponsor: International Breast Cancer Study Group
Active, not recruiting --> Terminated; low accrual Recruiting --> Active, not recruiting
- | letrozole / Generic mfg.
Enrollment closed: SOLE: Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=4800, Active, not recruiting, Sponsor: International Breast Cancer Study Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Enrollment change: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Jul 18, 2012
P2, N=84, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting N=28 --> 84
- letrozole / Generic mfg., anastrozole / Generic mfg., gefitinib / Generic mfg.
Trial completion, Metastases: Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy (clinicaltrials.gov) - Jul 16, 2012
P2, N=44, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=28 --> 84 Active, not recruiting --> Completed
- | letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
New P2 trial: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Jul 15, 2012
P2, N=84, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- letrozole / Generic mfg.
Enrollment change: Aromatase Inhibitors for Treatment of Uterine Leiomyomas (clinicaltrials.gov) - Jul 11, 2012
P1, N=0, Withdrawn, Sponsor: American University of Beirut Medical Center
Active, not recruiting --> Completed N=10 --> 0